Liraglutide Injection shortage (US): status and presentations
Shortage United States · first listed 18 July 2023 · updated 14 October 2026
| Dosage form | Injection |
|---|---|
| Therapy area | Endocrinology/Metabolism |
| Presentations | 0 unavailable, 3 limited, 6 available |
| Source | US FDA Drug Shortage Database (openFDA), checked 19 October 2026 |
Presentations affected
- Saxenda, Injection, 6 mg/1 mL — Limited Availability
- Victoza, Injection, 6 mg/1 mL — Limited Availability
- Liraglutide, Injection, 6 mg/1 mL — Available
Strengths and packs as listed by the regulator. Manufacturer names and product codes are not shown.
What buyers can do
- Check whether other registered presentations or strengths can be used, and ask your wholesaler about allocation.
- For hospital and tender supply, look for manufacturers that already hold an approval in your market and can increase output.
- In a critical shortage, the FDA can allow temporary importation of a version approved in a well-regulated market. That decision is made by the FDA, case by case.
- Qualify any new source as carefully as at any other time: GMP certificate, registration status and a certificate of analysis for each batch.
See the product page for Liraglutide Injection on PharmaTradz.
More: where licensed suppliers can step in during US shortages.
Need Liraglutide Injection?
Send a request with your market, strength and quantity. We match licensed buyers with qualified suppliers.
Request a quote I can supply thisFollow this shortage
We email you when its status changes. Confirm first; unsubscribe any time.
Related shortages
For information only. Shortage status changes often; confirm with the regulator before making decisions. Brand names, where shown, are trademarks of their owners.
